{'fraction_non_alphanumeric': 0.025728987993138937, 'fraction_numerical': 0.0, 'mean_word_length': 6.3924050632911396, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long‐Term Follow‐Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis (RRP) is a primarily benign disease affecting the entire respiratory tract. Treatment is challenging and usually involves surgical interventions and adjuvant medications. Previously, promising results on systemic administration of bevacizumab have been reported. However, experience on long‐term systemic use in patients with RRP is not yet available. Here, we present our long‐term follow‐up on RRP patients undergoing systemic bevacizumab treatment.